Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of r (Q57316368)
Jump to navigation
Jump to search
article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of r |
article |
Statements
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT) (English)
Jarir Atthobari
Cornelis Boersma
Robin de Vries
Ron T Gansevoort
Paul E de Jong
Lolkje T W de Jong-van den Berg
Maarten J Postma
PREVEND IT Study Group